Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High-dose Chemotherapy in Young Children with High-risk Medulloblastoma
NCT02025881Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Sep 2013
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide and busulfan in medulloblastoma, sponsored by Gustave Roussy. Primary endpoints: Maximum Tolerated Dose at 12 months and Event Free Survival at 3 years. Started Sep 2013; status: terminated.
02
Drugs
cyclophosphamidebusulfan
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT02025881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025881.